HighTower Advisors’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-85,972
| Closed | -$776K | – | 3960 |
|
|
2025
Q4 | $776K | Sell |
85,972
-25,269
| -23% | -$189K | ﹤0.01% | 2302 |
|
|
2025
Q3 | $346K | Sell |
111,241
-7,530
| -6% | -$19.9K | ﹤0.01% | 2914 |
|
|
2025
Q2 | $254K | Sell |
118,771
-4,500
| -4% | -$7.27K | ﹤0.01% | 3075 |
|
|
2025
Q1 | $142K | Buy |
123,271
+18,985
| +18% | +$32.6K | ﹤0.01% | 3282 |
|
|
2024
Q4 | $228K | Buy |
104,286
+331
| +0.3% | +$750 | ﹤0.01% | 3099 |
|
|
2024
Q3 | $227K | Buy |
103,955
+4,500
| +5% | +$10.3K | ﹤0.01% | 3044 |
|
|
2024
Q2 | $230K | Buy |
99,455
+1,921
| +2% | +$7.98K | ﹤0.01% | 2935 |
|
|
2024
Q1 | $537K | Sell |
97,534
-18,557
| -16% | -$84.9K | ﹤0.01% | 2231 |
|
|
2023
Q4 | $287K | Sell |
116,091
-9,003
| -7% | -$85.5K | ﹤0.01% | 2738 |
|
|
2023
Q3 | $4.34M | Sell |
125,094
-72
| -0.1% | -$2.49K | 0.01% | 990 |
|
|
2023
Q2 | $4.11M | Buy |
125,166
+271
| +0.2% | +$9.34K | 0.01% | 991 |
|
|
2023
Q1 | $4.18M | Sell |
124,895
-27,817
| -18% | -$1.08M | 0.01% | 936 |
|
|
2022
Q4 | $5.01M | Buy |
152,712
+131
| +0.1% | +$3.88K | 0.01% | 855 |
|
|
2022
Q3 | $5.33M | Hold |
152,581
| – | – | 0.01% | 778 |
|
|
2022
Q2 | $1.87M | Buy |
+152,581
| New | +$2.28M | ﹤0.01% | 1303 |
|
Other funds holding VTYX
HighTower Advisors's VTYX Position: Q1 2026 in Review
HighTower Advisors sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 85,972 shares — an estimated $776K sold.
HighTower Advisors first reported a position in VTYX in Q2 2022 and held it in 15 quarters. The position peaked at $5.33M in Q3 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- HighTower Advisors reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- HighTower Advisors sold 85,972 Ventyx Biosciences shares in Q1 2026, an estimated $776K.
- HighTower Advisors first reported a position in Ventyx Biosciences in Q2 2022 and held it in 15 quarters.
- HighTower Advisors's Ventyx Biosciences position peaked at $5.33M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.